WallStSmart

DaVita HealthCare Partners Inc (DVA)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 292619% more annual revenue ($13.84B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 5.7%. NIVF trades at a lower P/E of 0.0x. DVA earns a higher WallStSmart Score of 70/100 (B-).

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

NIVF

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVASignificantly Overvalued (-17.0%)

Margin of Safety

-17.0%

Fair Value

$123.34

Current Price

$192.16

$68.82 premium

UndervaluedFair: $123.34Overvalued

Intrinsic value data unavailable for NIVF.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.658/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

NIVF6 strengths · Avg: 9.8/10
P/E RatioValuation
0.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Return on EquityProfitability
79.4%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
209.0%10/10

Keeps 209 of every $100 in revenue as profit

Altman Z-ScoreHealth
4.0710/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

NIVF3 concerns · Avg: 2.7/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.77M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
-349.1%1/10

Operating margin of -349.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bull Case : NIVF

The strongest argument for NIVF centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : NIVF

The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

DVA profiles as a value stock while NIVF is a mature play — different risk/reward profiles.

DVA carries more volatility with a beta of 0.91 — expect wider price swings.

NIVF is growing revenue faster at 11.9% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (70/100 vs 58/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

NewGenIvf Group Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

NewGenIvf Group Limited (NIVF) is a prominent player in the reproductive health sector, specializing in innovative fertility solutions and advanced in vitro fertilization (IVF) services. With a commitment to enhancing success rates in assisted reproductive technology, NIVF is well-positioned to capitalize on the growing global demand for fertility treatments, supported by an extensive network of clinics and strategic partnerships. As the fertility services market continues to evolve, NIVF is positioned for considerable growth, dedicated to empowering individuals and couples in their journey to parenthood.

Want to dig deeper into these stocks?